Storytelling, Awareness, and the Race Against Time in Duchenne Muscular Dystrophy

By Helena Marsh

Why Awareness May Be the Most Powerful Tool Rare Disease Families Have

When parents of children with Duchenne muscular dystrophy gather to discuss their lives, the conversation rarely begins with genetics. It does not begin with regulatory pathways, reimbursement policies, or pharmaceutical pricing either. More often than not, it begins with something far simpler and far more universal: time.

Time before a child loses the ability to run. Time before climbing stairs becomes a challenge. Time before a wheelchair becomes a necessity rather than a possibility. Time before a treatment that is available somewhere else in the world finally reaches the country where their child happens to live.

For families confronting Duchenne, time is not an abstract concept. It is the lens through which every decision is made and every future is evaluated. That reality was impossible to ignore during a recent conversation with Thomas Bartlett, a Boston-based rare disease advocate whose work spans patient organizations, expanded access initiatives, industry engagement, and public awareness efforts. Although Bartlett himself does not live with Duchenne, he has spent years immersed in the broader rare disease community and has become increasingly involved in discussions surrounding patient access, advocacy, and the role public awareness plays in accelerating change.

What emerged from that conversation was not simply a discussion about healthcare policy or pharmaceutical innovation. Instead, it became a broader reflection on why some diseases capture the world’s attention while others remain largely invisible, and why the ability to tell a compelling story may ultimately influence outcomes just as much as scientific progress itself.

The conversation began with the situation currently unfolding in Georgia, where families affected by Duchenne muscular dystrophy have spent years campaigning for access to therapies available in other countries. Their efforts have included meetings with government officials, public demonstrations, media outreach, and direct engagement with policymakers. Like many rare disease advocates around the world, they have found themselves navigating a difficult reality in which treatments may exist, scientific evidence may exist, and patients certainly exist, yet access remains out of reach.

Bartlett was not previously familiar with the specifics of the Georgian case, but he immediately recognized the broader pattern. Across the rare disease landscape, families routinely encounter a gap between scientific advancement and practical access. Medical innovation continues to move forward, sometimes at extraordinary speed, while healthcare systems, reimbursement structures, and regulatory frameworks often struggle to keep pace. The result is a situation in which patients may watch promising therapies emerge while remaining uncertain whether they will ever benefit from them.

This tension becomes particularly acute in rare diseases because of the economics involved. Developing therapies for small patient populations requires enormous investments of time, expertise, and capital. Clinical trials can take years. Regulatory reviews can take years more. Manufacturing specialized therapies often adds another layer of complexity and cost. When all of those factors are combined, the resulting treatments frequently carry price tags that challenge even the wealthiest healthcare systems.

Bartlett illustrated this reality through his own experience. He described receiving an FDA-approved therapy for myasthenia gravis that carries a seven-figure annual cost annually, a figure that would seem almost unimaginable outside the world of rare diseases. Emerging gene therapies and cellular therapies may cost even more. These figures immediately expose the uncomfortable question sitting beneath many access debates: how should societies allocate limited healthcare resources when a single treatment can cost millions of dollars and benefit only a relatively small number of patients?

The question is difficult enough when discussed in a boardroom or government office. It becomes significantly more difficult when viewed through the eyes of a parent.

Healthcare administrators may focus on sustainability. Policymakers may focus on budget impact. Pharmaceutical companies may focus on recovering the immense investments required to develop innovative treatments. Parents, however, are focused on something else entirely. They are focused on the progression of a disease that will not pause while those discussions take place. They understand that every year lost waiting for a decision may represent abilities their child will never recover.

It is precisely because these debates are so complex that Bartlett repeatedly returned to a theme that surfaced throughout the interview: storytelling.

While scientific evidence remains essential and economic analyses remain unavoidable, public awareness campaigns have historically succeeded not because they changed the underlying science but because they changed public perception. Human beings respond to stories. They connect with individuals. They remember faces, families, and personal experiences long after they have forgotten statistics.

To illustrate this point, Bartlett pointed to one of the most successful advocacy campaigns in recent history: the ALS Ice Bucket Challenge. More than a decade after it captured global attention, the campaign remains a powerful example of what can happen when a disease that previously existed largely outside public consciousness suddenly enters mainstream conversation. What began as a simple social media phenomenon evolved into a movement that dramatically increased awareness, generated unprecedented funding, and accelerated research efforts around the world.

The significance of that example extends well beyond ALS. The Ice Bucket Challenge demonstrated that public attention can become a catalyst for scientific progress, philanthropic investment, and political engagement. Once enough people begin paying attention, priorities change. Research receives funding. Policymakers become interested. Journalists start asking questions. Pharmaceutical companies see opportunities. Entire ecosystems begin to shift.

For Duchenne families, the lesson is both encouraging and frustrating.

Encouraging because awareness has the power to influence outcomes. Frustrating because awareness itself often feels unevenly distributed. Some diseases become widely recognized and benefit from substantial public support, while others remain largely unknown outside the communities directly affected by them.

When asked why this disparity exists, Bartlett suggested that emotional connection plays a significant role. People are naturally drawn to stories that allow them to imagine themselves, their children, or their loved ones in similar circumstances. Diseases affecting children often create particularly strong emotional responses because they challenge deeply held assumptions about fairness and vulnerability. The image of a child gradually losing physical abilities resonates in ways that many clinical descriptions never could.

This observation helps explain why so many successful rare disease advocacy efforts place patient experiences at their center. The objective is not merely to generate sympathy. Rather, it is to transform abstract medical conditions into human stories that audiences can understand and remember.

The Georgian families provide a compelling example of this approach. Their struggle is not unique, but their willingness to speak publicly about it has created opportunities for broader engagement. Every interview, every article, every social media post, and every public demonstration contributes to making an invisible problem more visible. Whether those efforts ultimately change policy remains to be seen, but history suggests that meaningful change rarely occurs before awareness exists.

The role of journalism becomes particularly important within this context. During the interview, Bartlett highlighted organizations such as Rare Disease Advisor and CheckRare, both of which have invested heavily in patient-centered storytelling. Their work reflects an understanding that technical information alone is rarely sufficient to mobilize audiences. Scientific breakthroughs matter, but people tend to engage more deeply when those breakthroughs are connected to the lives of real individuals.

This is especially relevant in Duchenne muscular dystrophy, where discussions can easily become dominated by complex terminology related to genetics, biomarkers, regulatory approvals, and clinical trial design. While those topics are undeniably important, they often obscure the human reality beneath them. Every reimbursement decision affects a family. Every delayed approval affects a child. Every policy discussion eventually reaches a kitchen table where parents are trying to determine what comes next.

Perhaps the most revealing moment of the conversation came near its conclusion, when Bartlett was asked what gives him hope about the future. His answer did not focus on a particular company, therapy, or clinical trial. Instead, he spoke about people. He spoke about scientists pursuing solutions to extraordinarily difficult problems, researchers challenging long-standing assumptions, and innovators developing technologies that would have seemed impossible only a generation ago.

His optimism was not rooted in certainty. Anyone familiar with rare diseases understands that progress is rarely linear and that setbacks are inevitable. Rather, it was rooted in confidence that talented, dedicated individuals continue working toward solutions even when the challenges appear overwhelming.

That perspective feels particularly relevant today. The rare disease community has never possessed more scientific knowledge than it does now. Gene therapies, cellular therapies, artificial intelligence, precision medicine, and advances in molecular biology are creating opportunities that previous generations could scarcely imagine. Yet scientific progress alone will not guarantee access. It will not automatically create public awareness. It will not ensure that policymakers understand the urgency families experience every day.

That is where storytelling enters the picture.

Throughout the interview, Bartlett returned repeatedly to the importance of educating the public, engaging communities, amplifying patient voices, and helping people understand what life with a rare disease actually looks like. In many ways, that message may be the most important takeaway from the conversation. Scientific breakthroughs can transform lives, but before societies invest in those breakthroughs, before governments fund them, and before healthcare systems prioritize them, people must first care enough to pay attention.

For families living with Duchenne muscular dystrophy, awareness is therefore more than a communications strategy. It is more than advocacy. It is more than public relations.

It is often the first step toward research funding, regulatory action, policy change, and ultimately access to treatment.

In that sense, storytelling is not merely about sharing experiences.

It is about creating the conditions under which change becomes possible.

And for families racing against a disease that never stops progressing. For rare disease families, awareness is not the end goal.

It is often the beginning of everything that follows.

Research.

Funding.

Policy.

Access.

Hope.

Before treatments can change lives, people must first understand why those lives matter.

That is why storytelling remains one of the most powerful medicines rare disease communities have.